Cell and Gene Therapy

We believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients’ lives. Innovation, collaboration, and diversity in skills, backgrounds and experiences help us come up with best possible solutions for patients.
Cell and gene therapies are one such area of innovation, and one that offers tremendous promise for the treatment of serious diseases.

With gene therapy, genetic code that is responsible for a disease is removed, modified, or replaced. With cell therapy, cells may be modified to prompt an immune response to a specific tumor, for example, once introduced to a patient. But how are these advances in the lab translated into therapies for patients?

To address these challenges, Roche recently formed a new organization focusing on end-to-end CMC (Chemistry, Manufacturing & Controls) development and manufacturing of cell and gene therapies: Pharma Technical Cell & Gene Therapy (PTC).

Markus Haindl, who heads the new PTC Gene Therapy unit, explains, "In order to make these new therapies available to patients worldwide, we need to think in new paradigms. We are deeply committed to go beyond the current state of the art, and beyond what we think is possible for developing and manufacturing gene therapies. Our Gene Therapy Development Center south of Munich will be the core element and nucleus of this work."

Cross-functional collaborations, empowerment, and our learning culture help us to get better every day and fulfill our purpose: “Doing now what patients need next."

Working at Roche means working at the forefront of innovation. You will have the opportunity not only to learn and move forward but also to make your mark.

Learn more about our culture here.